<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166346</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00090799</org_study_id>
    <nct_id>NCT02166346</nct_id>
    <nct_alias>NCT01446575</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)</brief_title>
  <official_title>Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transverse myelitis (TM) is an inflammatory disorder of the spinal cord that leads to
      disabilities of gait. Dalfampridine, a sustained-release potassium inhibitor has been shown
      to be effective in improving gait and other neurologic functions in multiple sclerosis.
      Dalfampridine has the potential to improve neurologic function in patients with transverse
      myelitis as this rare disorder shares a similar pathogenic process with multiple sclerosis.
      The in a clinical trial to test the efficacy of dalfampridine in TM.

      The clinical trial that the investigators propose to conduct will focus on TM and will
      evaluate the dalfampridine in primary neurologic outcome, 25-foot timed walk, and several
      secondary outcomes including valid behavioral and neurophysiological tests.

      This is a re-launch of the previous trial, which now includes additional behavioral and
      clinical testing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fampridine (4-aminopyridine) is a potassium channel blocker that has been studied since the
      1970s for its effect on amplifying conductivity in peripheral nerves, potentiating
      neurotransmitter release in muscles and increasing post-synaptic action potentials in the
      spinal cord. It was tested in other neurologic conditions over the next two decades and was
      found to have a limited therapeutic window due to the stimulation of seizures at high doses.
      The first randomized, placebo-controlled, double-blinded study of fampridine in 70 patients
      found significant improvements in a number of neurophysiological parameters while on
      fampridine compared to placebo. Since then, at least six additional studies on oral
      fampridine in Multiple Sclerosis (MS) were conducted and found to have some significant
      neurologic function. Although only a small incidence of seizure or altered mental status were
      reported in these studies, the concern about fampridine causing seizures remained a barrier
      in the acceptance of fampridine as an MS therapy in the general neurology community.

      Recently, Biogen-Idec and Acorda have teamed up in the development of a sustained-release
      formulation of fampridine, dalfampridine, in which plasma concentrations of the drug and
      avoids toxic doses that lead to seizures. In two clinical trials, dalfampridine has been
      shown to be beneficial in two large cohorts of multiple sclerosis patients with noted
      improvements in gait and lower extremity muscle strength. Seizures were only seen in high
      doses of 20 mg or more whereas benefits were evident at the approved dose of 10 mg twice
      daily.

      The Food and Drug Administration (FDA) approved dalfampridine for use in multiple sclerosis
      in 2009 based on the key study that evaluated gait by timed 25-foot walk. About 35-40% of
      study participants responded and this group improved their walking speed by about 20%.

      The investigator's interest in dalfampridine is focused more narrowly on a subset of patients
      with a demyelinating disorder that is restricted to the spinal cord, transverse myelitis
      (TM), was not included in any previous human trials of dalfampridine. In contrast to MS,
      which affects the entire system, transverse myelitis affects the spinal cord and largely
      spares the brain. It is not associated with an increased risk of seizure.

      Transverse myelitis is defined as an episode of inflammation in the spinal cord leading to
      disability at the level of the lesion and below. The majority of TM lesions strike the
      thoracic cord causing impairments in lower extremities. A single lesion is the cause of all
      of their symptoms. The goal of using dalfampridine in these patients is to amplify axonal
      conductance across the lesion. This would manifest as improved neurologic function involving
      the lower extremities including gait. This is a straightforward proof of concept model
      proving the mechanism of action of dalfampridine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">January 8, 2017</completion_date>
  <primary_completion_date type="Actual">January 8, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Walking Speed During Timed 25-foot Walk</measure>
    <time_frame>Every 2 weeks during each 8 week intervention</time_frame>
    <description>In this cross-over study, walking speed was recorded 4 times for each subject while in both the dalfampridine and placebo arms. The results average all of the times while on damfampridine and compares them to the average of the times while on placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper and Lower Extremity Muscle Strength Measurements</measure>
    <time_frame>baseline and end (8 weeks) of each intervention</time_frame>
    <description>Upper and lower extremity muscle strength measurements, using a hand held dynamometer, at the beginning and end of each arm. Change in muscle strength between baseline and end (8 weeks) of each intervention are provided.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Transverse Myelitis</condition>
  <condition>Neuromyelitis Optica</condition>
  <condition>Idiopathic Transverse Myelitis</condition>
  <condition>Myelitis NOS</condition>
  <arm_group>
    <arm_group_label>Dalfampridine then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo the Dalfampridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalfampridine</intervention_name>
    <description>Dalfampridine 10 mg twice daily for 8 weeks</description>
    <arm_group_label>Dalfampridine then Placebo</arm_group_label>
    <arm_group_label>Placebo the Dalfampridine</arm_group_label>
    <other_name>Ampyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill 1 tablet twice daily for 8 weeks</description>
    <arm_group_label>Dalfampridine then Placebo</arm_group_label>
    <arm_group_label>Placebo the Dalfampridine</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of transverse myelitis confirmed by MRI

          -  Gait impairment defined as a baseline timed 25-foot walk of at least 5 seconds and no
             more than 60 seconds.

          -  Age 18-70.

        Exclusion Criteria:

          -  Diagnosis of any of the following concurrent conditions: spinal dural arteriovenous
             malformation, multiple sclerosis, infectious myelitis and recurrent transverse
             myelitis of any etiology. Subjects with a positive NMO-Immunoglobulin G (IgG)
             biomarker test will be permitted to join the study as long as the there is only a
             history of monophasic, and not recurrent, TM.

          -  History of seizure(s).

          -  Pregnancy or positive pregnancy test (mandatory test for all women aged 18-55 to be
             done at first screening visit).

          -  Known use or allergy to dalfampridine or any other formulation of 4-aminopyridine.

          -  Patients unable to walk.

          -  Patients with history of severe alcohol or drug abuse, severe psychiatric illness such
             as severe depression, poor motivational capacity, or severe language disturbances,
             particularly of receptive nature or with serious cognitive deficits (defined as
             equivalent to a mini-mental state exam score of 23 or less).

          -  Patients with severe uncontrolled medical problems (e.g. hypertension, cardiovascular
             disease, severe rheumatoid arthritis, active joint deformity of arthritic origin,
             active cancer or renal disease, any kind of end-stage pulmonary or cardiovascular
             disease, claudication, uncontrolled epilepsy or others).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Levy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <results_first_submitted>January 12, 2018</results_first_submitted>
  <results_first_submitted_qc>March 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2018</results_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transverse myelitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
    <mesh_term>Myelitis</mesh_term>
    <mesh_term>Myelitis, Transverse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dalfampridine Then Placebo</title>
          <description>All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.
Dalfampridine: Dalfampridine 10 mg twice daily for 8 weeks Placebo: Placebo pill 1 tablet twice daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Dalfampridine</title>
          <description>All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.
Placebo: Placebo pill 1 tablet twice daily for 8 weeks Dalfampridine: Dalfampridine 10 mg twice daily for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening and Randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention - Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention - Phase 2 (After Crossover)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>24 participants consented, 8 were excluded = 16 enrolled. Of the 16 enrollees, 3 withdrew = 13 completers.</population>
      <group_list>
        <group group_id="B1">
          <title>Whole Study Population</title>
          <description>This is a crossover trial. At baseline prior to randomization into an intervention, the baseline measures are provided.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="33" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Disease</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" lower_limit="3" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale score</title>
          <description>In this scale, 0 is normal and 10 is dead. Additional information can be found here: https://www.mstrust.org.uk/a-z/expanded-disability-status-scale-edss</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" lower_limit="3.5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion location within spinal cord</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cervical</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cervicothoracic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Thoracic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion length by MRI</title>
          <description>Vertebral length is defined as the number of vertebrae between the top of the T2 hyper intense lesion by MRI and the bottom of the lesion visualized on the middle sagittal section.</description>
          <units>vertebral lengths</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="2" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Walking Speed During Timed 25-foot Walk</title>
        <description>In this cross-over study, walking speed was recorded 4 times for each subject while in both the dalfampridine and placebo arms. The results average all of the times while on damfampridine and compares them to the average of the times while on placebo.</description>
        <time_frame>Every 2 weeks during each 8 week intervention</time_frame>
        <population>In this cross-over study, walking speed was recorded 4 times for each subject while in both the dalfampridine and placebo arms. The results average all of the times while on damfampridine and compares them to the average of the times while on placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>All subjects will be randomized for the first double-blinded 8-week part of the study with 25-foot timed walking assessments every 2 weeks. Then subjects will be crossed over to the other therapy (drug or placebo) for another 8 weeks.
Dalfampridine: Dalfampridine 10 mg twice daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo controlled arm.
Placebo: Placebo pill 1 tablet twice daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Speed During Timed 25-foot Walk</title>
          <description>In this cross-over study, walking speed was recorded 4 times for each subject while in both the dalfampridine and placebo arms. The results average all of the times while on damfampridine and compares them to the average of the times while on placebo.</description>
          <population>In this cross-over study, walking speed was recorded 4 times for each subject while in both the dalfampridine and placebo arms. The results average all of the times while on damfampridine and compares them to the average of the times while on placebo.</population>
          <units>feet/second</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3342" lower_limit="0.0975" upper_limit="0.5709"/>
                    <measurement group_id="O2" value="0.4745" lower_limit="0.2294" upper_limit="0.7195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4593" lower_limit="0.2071" upper_limit="0.7114"/>
                    <measurement group_id="O2" value="0.1743" lower_limit="-0.06251" upper_limit="0.4111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5445" lower_limit="0.1018" upper_limit="0.9872"/>
                    <measurement group_id="O2" value="0.5697" lower_limit="0.1596" upper_limit="0.9799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3803" lower_limit="-0.0113" upper_limit="0.7719"/>
                    <measurement group_id="O2" value="0.2101" lower_limit="-0.1757" upper_limit="0.5959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Upper and Lower Extremity Muscle Strength Measurements</title>
        <description>Upper and lower extremity muscle strength measurements, using a hand held dynamometer, at the beginning and end of each arm. Change in muscle strength between baseline and end (8 weeks) of each intervention are provided.</description>
        <time_frame>baseline and end (8 weeks) of each intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>All subjects will be randomized for the first double-blinded 8-week part of the study with 25-foot timed walking assessments every 2 weeks. Then subjects will be crossed over to the other therapy (drug or placebo) for another 8 weeks.
Dalfampridine: Dalfampridine 10 mg twice daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo controlled arm.
Placebo: Placebo pill 1 tablet twice daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Upper and Lower Extremity Muscle Strength Measurements</title>
          <description>Upper and lower extremity muscle strength measurements, using a hand held dynamometer, at the beginning and end of each arm. Change in muscle strength between baseline and end (8 weeks) of each intervention are provided.</description>
          <units>Pounds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine Left Hip Flexor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".6420" lower_limit="-7.3278" upper_limit="8.6118"/>
                    <measurement group_id="O2" value="-0.05187" lower_limit="-6.3646" upper_limit="6.2609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine Right Hip Flexor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5774" lower_limit="-2.4644" upper_limit="7.6192"/>
                    <measurement group_id="O2" value="2.854" lower_limit="-1.31" upper_limit="7.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prone Left Hip Flexor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.286" lower_limit="-6.5985" upper_limit="13.1717"/>
                    <measurement group_id="O2" value="-1.497" lower_limit="-10.053" upper_limit="7.0572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prone Right Hip Flexor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9752" lower_limit="-6.8518" upper_limit="14.8022"/>
                    <measurement group_id="O2" value="-4.4162" lower_limit="-13.7929" upper_limit="4.9604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Grip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1594" lower_limit="-4.844" upper_limit="11.1628"/>
                    <measurement group_id="O2" value="-2.9007" lower_limit="-10.7863" upper_limit="4.9849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Grip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3602" lower_limit="-6.7146" upper_limit="3.9942"/>
                    <measurement group_id="O2" value="2.1665" lower_limit="-3.1048" upper_limit="7.4378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dalfampridine</title>
          <description>All subjects will be randomized for the first double-blinded 8-week part of the study with 25-foot timed walking assessments every 2 weeks. Then subjects will be crossed over to the other therapy (drug or placebo) for another 8 weeks.
Dalfampridine: Dalfampridine 10 mg twice daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo controlled arm.
Placebo: Placebo pill 1 tablet twice daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Muscle stiffness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Levy, Principal Investigator</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>443-287-4412</phone>
      <email>mlevy@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

